|Dr. Michael M. Goldberg M.D., M.B.A.||CEO, Pres & Director||250.64k||N/A||58|
|Mr. Jed A. Latkin||CFO, COO, Sec. & Treasurer||286.21k||N/A||43|
|Dr. Frederick O. Cope Ph.D., F.A.C.N., C.N.S.||Chief Scientific Officer & Sr. VP||340.57k||N/A||70|
|Mr. William J. Regan||Chief Compliance Officer and Sr. VP of Global Regulatory Affairs & Quality||305.14k||N/A||65|
|Sharon Correia||Sr. Director of Corp. Communications||N/A||N/A||N/A|
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Navidea Biopharmaceuticals, Inc’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 5; Compensation: 7.